A Department of Health and Human Services official delivered an ultimatum to Dr. Peter Marks: either resign or be fired.

Pantheon Vision has signed a deal with Eyedeal Medical to advance the manufacturing of its corneal implants for treating ...

FDA pick, a former Johns Hopkins surgeon, seen as a less controversial nomination than some of Trump's other HHS subagency ...

Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...

The Food and Drug Administration (FDA) has cautioned those taking a libido-boosting herbal dietary supplement after an ...

Diopsys, Inc., a medical device manufacturer based in Middletown, Pennsylvania, will pay up to $14.25 million to resolve ...

DelveInsight's "VUITY Market Size, Forecast, and Market Insight Report" highlights the details around VUITY, which is a ...

An estimated 45 million Americans wear them—and this recall affects at least two very recognizable brand names for eyes.

The demand for Marks to resign comes as the FDA is bracing for steep cuts at the ... senior federal health official said. "It was Peter's vision that made that work possible," the official added.

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

The Johns Hopkins surgeon will helm the agency as layoffs loom and important decisions on treatments for rare and infectious diseases await.

The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular ...